leadf
logo-loader
viewVolitionRx

VolitionRX encouraged by early data on its Nu.QTM blood test as potential tool against coronavirus

VolitionRx Limited's (NYSEAMERICAN:VNRX) Cameron Reynolds tells Proactive's Andrew Scott they've been investigating how its Nu.QTM platform might be clinically useful as either a diagnostic or prognostic tool for COVID-19 and that they've been encouraged by some of the early data.

He says they've recently conducted a proof of concept study involving 34 COVID-19 positive subjects and 50 control subjects.

The announcement was made alongside Volition's first quarter results which showed they ended the period with $12 million in cash and cash equivalents.

Quick facts: VolitionRx

Price: 3.05 USD

NYSEMKT:VNRX
Market: NYSEMKT
Market Cap: $146.16 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of VolitionRx named herein, including the promotion by the Company of VolitionRx in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

FutureVault collaboration with Iron Mountain looks to bring disruptive...

FutureVault CEO John Orr and Chief Marketing Officer Michael Bradley joined Steve Darling from Proactive to discuss a collaboration they are doing with Iron Mountain to engage their logistical network and physical information management infrastructure with FutureVault’s secure digital vault...

5 hours, 55 minutes ago

2 min read